We also found regorafenib significantly reduces tumor growth, NF‐κB activation, and protein levels of tumor progression‐associated proteins (MMP‐9, XIAP, VEGF, and Cyclin‐D1) in bladder cancer in vitro and in vivo. This evidence concerns the gene MMP9 and neoplasm.